Gene knockout of Gpx4 or treatment with low-dose Gpx4-targeted inhibitors could significantly diminish chemotherapy resistance in EBV-positive NPC cell lines, presenting a potential therapeutic target for treating chemotherapy-resistant tumors (35–37). Here, GPX4 is linked to nasopharyngeal carcinoma.